887 related articles for article (PubMed ID: 31307111)
1. Buprenorphine prescribing for opioid use disorder in medical practices: can office-based out-patient care address the opiate crisis in the United States?
Rhee TG; Rosenheck RA
Addiction; 2019 Nov; 114(11):1992-1999. PubMed ID: 31307111
[TBL] [Abstract][Full Text] [Related]
2. Injectable naltrexone, oral naltrexone, and buprenorphine utilization and discontinuation among individuals treated for opioid use disorder in a United States commercially insured population.
Morgan JR; Schackman BR; Leff JA; Linas BP; Walley AY
J Subst Abuse Treat; 2018 Feb; 85():90-96. PubMed ID: 28733097
[TBL] [Abstract][Full Text] [Related]
3. Buprenorphine Prescribing and Challenges Faced Among National Health Service Corps Clinicians.
Rowan K; Shah SV; Binns S; Murphy E; Satorius J; Ghobadi A; Krauss D; Robbins C; Schoebel V; Knudson A; Kepley H;
JAMA Netw Open; 2024 May; 7(5):e2411742. PubMed ID: 38758556
[TBL] [Abstract][Full Text] [Related]
4. Use of Medications for Treatment of Opioid Use Disorder Among US Medicaid Enrollees in 11 States, 2014-2018.
; Donohue JM; Jarlenski MP; Kim JY; Tang L; Ahrens K; Allen L; Austin A; Barnes AJ; Burns M; Chang CH; Clark S; Cole E; Crane D; Cunningham P; Idala D; Junker S; Lanier P; Mauk R; McDuffie MJ; Mohamoud S; Pauly N; Sheets L; Talbert J; Zivin K; Gordon AJ; Kennedy S
JAMA; 2021 Jul; 326(2):154-164. PubMed ID: 34255008
[TBL] [Abstract][Full Text] [Related]
5. Buprenorphine Receipt and Retention for Opioid Use Disorder Following an Initiative to Increase Access in Primary Care.
Hawkins EJ; Malte CA; Hagedorn HJ; Gordon AJ; Williams EC; Trim RS; Blanchard BE; Lott A; Danner AN; Saxon AJ
J Addict Med; 2024 May-Jun 01; 18(3):240-247. PubMed ID: 38329814
[TBL] [Abstract][Full Text] [Related]
6. A mixed-method comparison of physician-reported beliefs about and barriers to treatment with medications for opioid use disorder.
Haffajee RL; Andraka-Christou B; Attermann J; Cupito A; Buche J; Beck AJ
Subst Abuse Treat Prev Policy; 2020 Sep; 15(1):69. PubMed ID: 32928272
[TBL] [Abstract][Full Text] [Related]
7. Racial Inequality in Receipt of Medications for Opioid Use Disorder.
Barnett ML; Meara E; Lewinson T; Hardy B; Chyn D; Onsando M; Huskamp HA; Mehrotra A; Morden NE
N Engl J Med; 2023 May; 388(19):1779-1789. PubMed ID: 37163624
[TBL] [Abstract][Full Text] [Related]
8. The association of Medicare Part D prior authorization for buprenorphine-naloxone with adherence to opioid use disorder treatment guidelines in the United States.
Parish WJ; Mark TL; Zarkin GA; Weber E
Addiction; 2022 Jan; 117(1):141-150. PubMed ID: 34033177
[TBL] [Abstract][Full Text] [Related]
9. Addressing System and Clinician Barriers to Emergency Department-initiated Buprenorphine: An Evaluation of Post-intervention Physician Outcomes.
Mahal JJ; Bijur P; Sloma A; Starrels J; Lu T
West J Emerg Med; 2024 May; 25(3):303-311. PubMed ID: 38801034
[TBL] [Abstract][Full Text] [Related]
10. Buprenorphine prescribing practice trends and attitudes among New York providers.
Kermack A; Flannery M; Tofighi B; McNeely J; Lee JD
J Subst Abuse Treat; 2017 Mar; 74():1-6. PubMed ID: 28132694
[TBL] [Abstract][Full Text] [Related]
11. Primary care physicians' preparedness to treat opioid use disorder in the United States: A cross-sectional survey.
Foti K; Heyward J; Tajanlangit M; Meek K; Jones C; Kolodny A; Alexander GC
Drug Alcohol Depend; 2021 Aug; 225():108811. PubMed ID: 34175786
[TBL] [Abstract][Full Text] [Related]
12. Racial and Ethnic Inequities in Buprenorphine and Methadone Utilization Among Reproductive-Age Women with Opioid Use Disorder: an Analysis of Multi-state Medicaid Claims in the USA.
Xu KY; Schiff DM; Jones HE; Martin CE; Kelly JC; Bierut LJ; Carter EB; Grucza RA
J Gen Intern Med; 2023 Dec; 38(16):3499-3508. PubMed ID: 37436568
[TBL] [Abstract][Full Text] [Related]
13. Are North Carolina clinicians delivering opioid use disorder treatment to Medicaid beneficiaries?
Grove LR; Rao N; Domino ME
Addiction; 2022 Nov; 117(11):2855-2863. PubMed ID: 35194878
[TBL] [Abstract][Full Text] [Related]
14. Concentration of Patient Care Among Buprenorphine-Prescribing Clinicians in the US.
Stein BD; Saloner B; Schuler MS; Gurvey J; Sorbero M; Gordon AJ
JAMA; 2021 Jun; 325(21):2206-2208. PubMed ID: 34061152
[TBL] [Abstract][Full Text] [Related]
15. Trends in Receipt of Buprenorphine and Naltrexone for Opioid Use Disorder Among Adolescents and Young Adults, 2001-2014.
Hadland SE; Wharam JF; Schuster MA; Zhang F; Samet JH; Larochelle MR
JAMA Pediatr; 2017 Aug; 171(8):747-755. PubMed ID: 28628701
[TBL] [Abstract][Full Text] [Related]
16. Geographic and specialty distribution of US physicians trained to treat opioid use disorder.
Rosenblatt RA; Andrilla CH; Catlin M; Larson EH
Ann Fam Med; 2015; 13(1):23-6. PubMed ID: 25583888
[TBL] [Abstract][Full Text] [Related]
17. Composition of buprenorphine prescribing networks in Medicaid and association with quality of care.
Zhu JM; Charlesworth CJ; Stein BD; Drake C; Polsky D; Korthuis PT; McConnell KJ
J Subst Use Addict Treat; 2024 Aug; 163():209363. PubMed ID: 38641055
[TBL] [Abstract][Full Text] [Related]
18. Variation in Use of Medications for Opioid Use Disorder in Critically Ill Patients Across the United States.
Feeney ME; Law AC; Walkey AJ; Bosch NA
Crit Care Med; 2024 Jul; 52(7):e365-e375. PubMed ID: 38501933
[TBL] [Abstract][Full Text] [Related]
19. Racial/ethnic disparities in timely receipt of buprenorphine among Medicare disability beneficiaries.
Miles J; Treitler P; Hermida R; Nyaku AN; Simon K; Gupta S; Crystal S; Samples H
Drug Alcohol Depend; 2023 Nov; 252():110963. PubMed ID: 37748421
[TBL] [Abstract][Full Text] [Related]
20. Buprenorphine use and disparities in access among emergency department patients with opioid use disorder: A cross-sectional study.
Robbins M; Haroz R; Mazzarelli A; Clements D; Jones CW; Salzman M
J Subst Abuse Treat; 2021 Nov; 130():108405. PubMed ID: 34118697
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
